Related Experiment Video
Updated: Apr 30, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Systemic hypertension in very preterm infants: a population-based study
Aseel Sa'deh1, Beth Ellen Brown2, Michael Vincer1
1Department of Pediatrics, IWK Health Centre, Dalhousie University, 5850/5980 University Ave., PO Box 9700, Halifax, NS, B3K 6R8, Canada.
Insights
Systemic hypertension (SH) affects 10.9% of very preterm infants, with incidence decreasing over time. Antenatal magnesium sulfate use was linked to lower SH odds, and SH did not negatively impact infant outcomes.
Area of Science:
- Neonatology
- Pediatric Cardiology
- Public Health
Background:
- Systemic hypertension (SH) in very preterm infants is a significant concern requiring further research.
- The incidence of SH in this population is not uncommon and warrants clinical attention.
Purpose of the Study:
- To assess the incidence, trends, risk factors, clinical features, management, and outcomes of SH in very preterm infants.
- To investigate the association between antenatal magnesium sulfate and the occurrence of SH.
- To evaluate the impact of SH on neonatal mortality, hospital stay, and neurodevelopmental outcomes.
Main Methods:
- A retrospective, population-based study of very preterm infants (<31 weeks' gestation) born between 2002 and 2016 in Nova Scotia and Prince Edward Island, Canada.
- Comparison of infants diagnosed with SH requiring treatment against matched controls.
- Review of perinatal data, SH details, neonatal course, and neurodevelopmental outcomes at 18 months corrected age.
Main Results:
- The incidence of SH was 10.9%, showing a significant decline from 12.8% to 7.2% over the 15-year study period.
- Intrapartum magnesium sulfate administration was associated with decreased odds of SH (aOR 0.25).
- No significant differences were observed in mortality, length of hospital stay, or neurodevelopmental scores between SH patients and controls.
Conclusions:
- The incidence of SH in very preterm infants is 10.9%, with a decreasing trend observed.
- Antenatal magnesium sulfate administration is associated with reduced odds of developing SH.
- Systemic hypertension in very preterm infants does not appear to be associated with adverse neonatal mortality, hospital stay, or neurodevelopmental outcomes at 18 months corrected age.
Abstract:
The purpose of this study is to assess incidence, temporal trend, risk factors, clinical characteristics, management and outcomes of systemic hypertension (SH) in very preterm infants. We conducted a retrospective population-based study including preterm infants born at < 31 weeks' gestation in Nova Scotia and Prince Edward Island, Canada, between 2002 and 2016. Patients diagnosed with SH requiring treatment before discharge from the NICU, or on 3 consecutive occasions during outpatient follow-up, were compared with matched controls (for gestational age, sex and birth weight). Perinatal data, details of SH, neonatal course and neurodevelopmental outcomes at 18 months corrected gestational age were reviewed. Of the 935 infants who met inclusion criteria, 102 (10.9%) had SH. Mean (SD) gestational age at birth was 27.1 (1.9) weeks. Median (IQR) corrected gestational age at diagnosis was 40 (37, 57) weeks. There was a significant reduction in the incidence of SH over the 15-year study period from 12.8 to 7.2% (p = 0.02). On logistic regression analysis, only intrapartum magnesium sulfate was associated with decreased odds of SH (aOR 0.25, 95% CI 0.08, 0.73). There were no significant differences in mortality, length of hospital stays, mean mental development index, cognitive, language, and motor scores between SH patients and their matched controls.
Conclusion:
The incidence of SH in very preterm infants was 10.9% with a declining trend over the study period. Administration of antenatal magnesium sulfate was associated with reduced odds of SH. Systemic hypertension does not appear to be negatively associated with neonatal mortality, length of hospital stay, or neurodevelopmental outcomes at 18 months corrected age.
What Is Known:
• Systemic hypertension in very preterm infants is not uncommon. • This significant health condition warrants more attention and research to guide clinical practice.
What Is New:
• The incidence of systemic hypertension in our study was 10.9% with a declining trend. • Approximately one third of infants were diagnosed after NICU discharge. • Approximately two thirds of the hypertensive infants had nephrocalcinosis. • Systemic hypertension was not associated with increased mortality, short-term morbidities, or neurodevelopmental impairment at 18 months corrected age.
Related Concept Videos
Hypertension I: Introduction
Measurement of Blood Pressure
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Increased Intracranial Pressure l: Introduction
Alterations in Blood Pressure
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...

